New Delhi, September 23: Bharat Biotech gets rights for nasal covid vaccine tech, eyes 100 crore doses as an intranasal vaccine will not only be simple to administer it will also reduce the use of medical consumables such as needles, syringes, etc.
Bharat Biotech will own the rights to distribute the nasal covid vaccine, subject to regulatory approvals, in all markets except the US, Japan and Europe.
The licensing agreements will lead to rapid clinical development, following the intranasal vaccine candidate having shown unprecedented levels of protection in mouse studies.
It added thaty the ability to accomplish effective immunization with a single nasal dose is a major advantage, offering broader reach and easier administration.
|